Safety and efficacy of Amniotic Membrane in Asherman's syndrome management

Phase 2

• Conditions: Asherman's Syndrome.; Intrauterine synechiae; N85.6

• Registration Number: IRCT20190714044201N1
• Lead Sponsor: Sarem Fertility and Infertility Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

Asherman's patients with intrauterine adhesions and endometrial atrophy
endometrial thickness of less than 5 mm
normal functioning of the heart kidneys and lungs
wish to complete the study

Exclusion Criteria

Unwilling to get pregnant
Genital tract inflammation
Cardiovascular diseases
Hormonal Problems Contraceptive Indication of Relative Hormone Therapy
Gastrointestinal diseases
prohibits estrogen use
liver or chronic hepatic failure
Immune system diseases such as lupus, ...
Past and present cancer
Positive serologic evidence of previous or current hepatitis B and C infection as well as HIV and HTLV

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Menstruation. Timepoint: At baseline and 3 and 6 months after intervention. Method of measurement: Number of menstruation days, pads number.;Endometrial thickness. Timepoint: At baseline and 3 and 6 months after intervention. Method of measurement: Ultrasound.

Secondary Outcome Measures

Name	Time	Method
Pregnancy Rate. Timepoint: 12 month 3 month time frame. Method of measurement: Pregnancy routine tests.;Implantation Rate. Timepoint: Pregnancy routine tests. Method of measurement: Ultrasound.